Revance Therapeutics (NASDAQ: RVNC) reported Q2 EPS of ($0.88), $0.02 worse than the analyst estimate of ($0.86). Revenue for the quarter came in at $75 thousand versus the consensus estimate of $70 thousand.

For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.